The Hollow Fibre Infection Model
Faster Development of Novel Anti-Infectives Therapies
The key to de-risking and expediting the development and approval of new antimicrobials lies in the detailed understanding of the PK/PD relationship.
Understanding this relationship informs the development of optimal human dosing, maximising efficacy while minimising the potential to antimicrobial resistance.
This whitepaper describes and appraises today's most versatile in vitro system for the determination of in vitro PK/PD relationships between antimicrobial compounds and bacteria, fungi and viruses - the Hollow Fibre Infection Model (HFIM), covering all areas including:
- The importance of non clinical PK/PD
- Why and when the HFIM should be used in the drug discovery process
- Evotec's HFIM expertise
Meet our Experts
Pia Thommes
VP Anti-Infectives
Virology Therapeutic
David Corbett
Group Leader
Anti-Infectives
Dive into our Science Pool
Keep ahead of the game and learn about exciting new research and trends within the Pharma industry.